Latest News

• PCCTC Study Shows Zytiga May Improve Outcomes When Taken Before P...

  Media Relations by admin March 1, 2015

  

  To address the need for better therapies for men with high-risk localized prostate cancer, Dr. Mary-Ellen Taplin of the Dana-Farber Cancer Institute led a multi...

  Learn More

• Radium Ra 223 dichloride (Xofigo Injection) FDA Approved for Cast...

  Press Releases by admin March 1, 2015

  

  On May15, 2013, the U. S. Food and Drug Administration (FDA) approved radium Ra 223 dichloride (Xofigo Injection, Bayer HealthCare Pharmaceuticals Inc.) for the...

  Learn More

• RFA: PCCTC Affiliate Clinical Research Sites

  Media Relations by admin March 1, 2015

  

  The PCCTC is now accepting applications for its Affiliate Clinical Research Site program. Key Dates RFA Issue date: July 22, 2014 Application deadline: Augus...

  Learn More

• PCCTC Trial Shows Tasquinimod Prolongs Survival in Metastatic Pro...

  Press Releases by admin March 1, 2015

  

  Survival data from a phase II PCCTC trial of single agent tasquinimod (NCT00560482) further support the development of this novel drug in men with minimally sym...

  Learn More

• New Test Differentiates Low- and High-Risk Prostate Cancer

  Press Releases by admin March 1, 2015

  

  Genomic Health, Inc. announced the launch of its Oncotype DX® prostate cancer test which can differentiate low-risk and aggressive tumors with up to 95% a...

  Learn More

• FDA Approves Abiraterone acetate (Zytiga) For Second Indication

  Press Releases by admin March 1, 2015

  

  On December 10, 2012, the U. S. Food and Drug Administration (FDA) approved an expanded indication for abiraterone acetate (Zytiga Tablets, Janssen Biotech, In...

  Learn More